COHERUS ONCOLOGY INC (CHRS) Stock Overview
USA - NASDAQ:CHRS - US19249H1032 - Common Stock
CHRS Key Statistics, Chart & Performance
The current stock price of CHRS is 1.68 USD. In the past month the price increased by 27.13%. In the past year, price increased by 57.69%.
CHRS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.68 | 405.51B | ||
| AMGN | AMGEN INC | 13.46 | 158.05B | ||
| GILD | GILEAD SCIENCES INC | 14.58 | 140.03B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.7 | 102.94B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.85 | 62.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.58B | ||
| ARGX | ARGENX SE - ADR | 85.47 | 48.49B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.51 | 37.49B | ||
| INSM | INSMED INC | N/A | 33.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.36B | ||
| NTRA | NATERA INC | N/A | 23.24B | ||
| BIIB | BIOGEN INC | 9.63 | 22.61B |
Related stock screener links
About CHRS
Company Profile
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 177 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
Company Info
COHERUS ONCOLOGY INC
333 Twin Dolphin Dr, Suite 600, 201 Redwood Shores Parkway, Suite 200
Redwood City CALIFORNIA 94065 US
CEO: Dennis M. Lanfear
Employees: 228
Phone: 16506493530
COHERUS ONCOLOGY INC / CHRS FAQ
What is the stock price of COHERUS ONCOLOGY INC today?
The current stock price of CHRS is 1.68 USD. The price increased by 2.44% in the last trading session.
What is the ticker symbol for COHERUS ONCOLOGY INC stock?
The exchange symbol of COHERUS ONCOLOGY INC is CHRS and it is listed on the Nasdaq exchange.
On which exchange is CHRS stock listed?
CHRS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for COHERUS ONCOLOGY INC stock?
11 analysts have analysed CHRS and the average price target is 5.78 USD. This implies a price increase of 244.05% is expected in the next year compared to the current price of 1.68. Check the COHERUS ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is COHERUS ONCOLOGY INC worth?
COHERUS ONCOLOGY INC (CHRS) has a market capitalization of 195.27M USD. This makes CHRS a Micro Cap stock.
How many employees does COHERUS ONCOLOGY INC have?
COHERUS ONCOLOGY INC (CHRS) currently has 228 employees.
What are the support and resistance levels for COHERUS ONCOLOGY INC (CHRS) stock?
COHERUS ONCOLOGY INC (CHRS) has a support level at 1.59 and a resistance level at 1.65. Check the full technical report for a detailed analysis of CHRS support and resistance levels.
Is COHERUS ONCOLOGY INC (CHRS) expected to grow?
The Revenue of COHERUS ONCOLOGY INC (CHRS) is expected to decline by -82.03% in the next year. Check the estimates tab for more information on the CHRS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy COHERUS ONCOLOGY INC (CHRS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CHRS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CHRS, evaluating the profitability, health, valuation and growth aspects
- COHERUS ONCOLOGY INC (CHRS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- COHERUS ONCOLOGY INC (CHRS) Sales and EPS estimates to see what analysts future expectations are.
- COHERUS ONCOLOGY INC (CHRS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- COHERUS ONCOLOGY INC (CHRS) Insider and Institutional Ownership to learn about the owners and their transactions.
- COHERUS ONCOLOGY INC (CHRS) Stock Chart to make your own analysis
- COHERUS ONCOLOGY INC (CHRS) Latest news and press-releases to stay up to date.
Does COHERUS ONCOLOGY INC (CHRS) stock pay dividends?
CHRS does not pay a dividend.
When does COHERUS ONCOLOGY INC (CHRS) report earnings?
COHERUS ONCOLOGY INC (CHRS) will report earnings on 2025-11-04, after the market close.
What is the Price/Earnings (PE) ratio of COHERUS ONCOLOGY INC (CHRS)?
COHERUS ONCOLOGY INC (CHRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.98).
What is the Short Interest ratio of COHERUS ONCOLOGY INC (CHRS) stock?
The outstanding short interest for COHERUS ONCOLOGY INC (CHRS) is 30.13% of its float. Check the ownership tab for more information on the CHRS short interest.
CHRS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CHRS. When comparing the yearly performance of all stocks, CHRS is one of the better performing stocks in the market, outperforming 94.71% of all stocks.
CHRS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CHRS. CHRS has a bad profitability rating. Also its financial health evaluation is rather negative.
CHRS Financial Highlights
Over the last trailing twelve months CHRS reported a non-GAAP Earnings per Share(EPS) of -0.98. The EPS increased by 27.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 125.9% | ||
| ROA | 40.9% | ||
| ROE | 150.01% | ||
| Debt/Equity | 0.42 |
CHRS Forecast & Estimates
11 analysts have analysed CHRS and the average price target is 5.78 USD. This implies a price increase of 244.05% is expected in the next year compared to the current price of 1.68.
For the next year, analysts expect an EPS growth of -66.6% and a revenue growth -82.03% for CHRS